LATHAM, N.Y. --(BUSINESS WIRE)--Nov. 17, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

AngioDynamics , The PERT Consortium™ and Viz.ai partner on APEX Study to facilitate future enrollment to bring innovative treatment to patients with PE LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 31, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused

Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51.9% declined 20 basis points year over year GAAP loss per

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 8, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 3, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 15, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--May 16, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--May 3, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Fiscal 2022 Third Quarter Highlights Net sales of $74.0 million increased 3.9% compared to the prior-year quarter Med Tech grew 28.6% and Med Device declined 2.8% year over year Gross margin of 52.2% declined 190 basis points year over year GAAP loss per share of $0.13 and adjusted earnings per

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 4, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system and improving quality of life for patients, today announced that Jim Clemmer , President

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 14, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 8, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 8, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, will

Fiscal 2022 Second Quarter Highlights Net sales of $78.3 million increased 7.6% compared to the prior-year quarter Med Tech growth of 36.4% and Med Device growth of 0.8% year over year Gross margin of 51.8% declined 340 basis points year over year GAAP loss per share of $0.21 , and adjusted loss

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 3, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 15, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of

Fiscal 2022 First Quarter Highlights Net sales of $77.0 million increased 9.6% compared to the prior-year quarter Gross margin of 52.1% increased 120 basis points year over year GAAP loss per share of $0.18 , and adjusted loss per share of $0.02 The Company commenced a Limited Market Release of its

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 15, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 29, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and